ASCO-GI: Overall Survival With Erbitux Is Significantly Improved In Patients With KRAS Wild-Type Tumors In CRYSTAL

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study…

More: continued here

Filed under: Cancer on January 25th, 2010